Abstract 4142400: Clinical implication and potential role of immunosuppression for myocarditis episodes in patients with desmoplakin cardiomyopathy: hope from the DSP-ERADOS Network?
Authors: Alessio Gasperetti, Giovanni Peretto, Steven Muller, mikael Laredo, Richard Carrick, Babken Asatryan, Alexandros Protonotarios, Brittney Murray, Paul Scheel, Kalliopi Pilichou, Petros Syrris, Max Jason, Kristen Medo, Valentina Rossi, Ardan Saguner, Robyn Hylind, Dominic Abrams, Julia Cadrin-Tourigny, iacopo olivotto, Elena Biagini, Moniek Cox, Philippe CHARRON, James Ware, Leonardo Cal, eric smith, Jodie Ingles, Flavie Ader, Stacey Peters, jeremy russo, Dominica Zentner, Eric Bahr, Eric Carruth, Chris Haggerty, Victoria Parikh, Matthew Taylor, Luisa Mestroni, Gianfranco Sinagra, Arthur Wilde, Estelle Gandjbakhch, Anneline Te Riele, Peter Van Tintelen, Perry Elliott, Luigi Adamo, Cynthia James, Marco Merlo, Neal Lakdawala, Barbara Bauce, Adam Helms, Hugh Calkins, Nisha Gilotra
Journal: Circulation (2024)

Introduction: Variants in the desmoplakin (DSP) gene are associated with a form of arrhythmogenic cardiomyopathy (ACM) characterized by high risk of ventricular arrhythmias (VAs), heart failure (HF), and recurrent myocarditis. The clinical implications and management of myocarditis episodes in DSP-ACM have been scarcely investigated and are a major unmet clinical challenge. Research Question: what is the clinical impact of myocarditis episodes in DSP-ACM? Is there any role for immunosuppression? Methods: Patients (pts) with DSP-ACM in the worldwide DSP-ERADOS Network (26 institutions across 9 countries in 3 continents) were enrolled. Pts were classified as myocarditis-positive (Myo+) if they had a diagnosis of myocarditis at any time as per ESC criteria and otherwise as negative (Myo-). A multi-state model was used to compare the time-dependent risk of the outcome of interest (combined occurrence of VAs or HF hospitalization) at follow up. Hazard ratios (HR) were reported for quantifying the impact of single or repeated myocarditis on combined outcome occurrences, as well as the impact of immunosuppression. Results: A total of 801 pts (38.8±17.3 yo, 63.9% female; LVEF 49.7±14.7%; RVEF 50.1±13.2%) were enrolled. Over 3.5 [1.2–6.7] years, 153 (19.1%) patients (Myo+) experienced 260 myocarditis episodes (1.7 episode/pt; n=54 pts with 2+ episodes), 79 of which were treated with immunosuppression. A total of 193 (24.1%; 6.7%/year) pts experienced the combined end-point (n=120/648 (18.5%) Myo-; n=73/153 (47.7%) Myo+; log rank p &lt;0.001). Occurrence of myocarditis was associated with increased risk in the composite outcome, with repeated myocarditis having a non-significant trend towards a higher risk than single events (Panel A). However, when adjusting for treatment with immunosuppressants in the Myo+ cohort, there were no differences in endpoint compared to pts in the Myo- cohort (Panel B) (Relative HR to Myo- pt: for treated Myo+ episodes: 0.76 [0.33–1.72], p=0.503; for untreated Myo+ episodes: 2.89 [2.11–3.95], p &lt;0.001). Application: Myocarditis episodes in pts with DSP-ACM are associated with increased risk in VA/HF hospitalizations. This analysis suggests a potential benefit of immunosuppression therapy for myocarditis episodes in DSP cardiomyopathy and warrants further study. Next Steps/Future: A randomized controlled trial is needed to test the role of immunotherapy in this patient population.